SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report its fourth quarter 2016 results after the Nasdaq market
closes on Tuesday, February 14, 2017.
Neurocrine will then host a live conference call and webcast
to discuss its financial results and provide a Company update
Tuesday afternoon, February 14, 2017
at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time).
Participants can access the live conference call by dialing
888-632-3382 (US) or 785-424-1677 (International) using the
conference ID NBIX. The call can also be accessed via the webcast
through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further
information on this announcement, please contact the Investor
Relations Department at Neurocrine Biosciences at (858) 617-7600.
A replay of the conference call will be available
approximately one hour after the conclusion of the call by dialing
800-839-6136 (US) or 402-220-2572 (International) using the
conference ID NBIX. The call will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals in diseases with high unmet
medical needs through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and INGREZZA, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement disorders.
Neurocrine plans to commercialize INGREZZA in the United States upon approval by the
FDA.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2016-results-300402890.html
SOURCE Neurocrine Biosciences, Inc.